Medical devices, healthcare technology and the business of care
PMA approval · P250034

Optune Pax

Novocure, GmbH · Decision date Feb 11, 2026

MEDTECHLEDGER EXPLANATIONP250034

What did the FDA approve?

FDA approved PMA P250034 for Optune Pax on February 11, 2026. The applicant is Novocure, GmbH, and the device is categorized as a low electric field generator for pancreatic cancer treatment under product code SHC.

The approval statement describes intended use in adult patients with locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel. The record does not include supplement type or supplement reason, so no change to a prior approval is documented here. The specialty field lists General, Plastic Surgery.

FDA approval order statement

Optune Pax is intended for treatment of adult patients with locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel.
Regulatory pathway
Original PMA
Clinical specialty
General, Plastic Surgery
Decision date
Feb 11, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250034
Regulatory pathway
Premarket approval application
Product code
SHC
Decision code
APPR
Decision date
Feb 11, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Low Electric Field Generator for Pancreatic Cancer Treatment.

Product code
SHC
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P250034 received

    Application receipt date recorded by FDA.

  2. P250034 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P250034. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250034

Product / regulatory recordCompanyPathwayDecision dateSource
Optune PaxP250034/S004
Novocure, GmbHPMA supplementOct 26, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Novocure, GmbH

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Neuhofstrasse 21, Baar, 6340

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records